EAM
RVNC

Exome Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Exome Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-347,600
Closed -$1.8M – 82
2024
Q3 		$1.8M Buy
+347,600
New +$1.73M 1.22% 36

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Exome Asset Management's RVNC Position: Q4 2024 in Review

Exome Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 347,600 shares — an estimated $1.8M sold.

Exome Asset Management first reported a position in RVNC in Q3 2024 and held it in 1 quarter. The position peaked at $1.8M in Q3 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Exome Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Exome Asset Management sold 347,600 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $1.8M.
  • Exome Asset Management first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 1 quarter.
  • Exome Asset Management's Revance Therapeutics, Inc. position peaked at $1.8M in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.